Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 2/10

vs
industry
vs
history
Cash to Debt 3.51
NSPH's Cash to Debt is ranked higher than
76% of the 291 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.74 vs. NSPH: 3.51 )
NSPH' s 10-Year Cash to Debt Range
Min: 0.2   Max: No Debt
Current: 3.51

Equity to Asset 0.73
NSPH's Equity to Asset is ranked higher than
80% of the 285 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.63 vs. NSPH: 0.73 )
NSPH' s 10-Year Equity to Asset Range
Min: -5.28   Max: 0.91
Current: 0.73

-5.28
0.91
F-Score: 4
Z-Score: -4.10
M-Score: -1.87
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) -337.14
NSPH's Operating margin (%) is ranked lower than
55% of the 287 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9.44 vs. NSPH: -337.14 )
NSPH' s 10-Year Operating margin (%) Range
Min: -2890.06   Max: -337.14
Current: -337.14

-2890.06
-337.14
Net-margin (%) -346.40
NSPH's Net-margin (%) is ranked lower than
55% of the 287 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.65 vs. NSPH: -346.40 )
NSPH' s 10-Year Net-margin (%) Range
Min: -4551.67   Max: -346.4
Current: -346.4

-4551.67
-346.4
ROE (%) -80.32
NSPH's ROE (%) is ranked lower than
51% of the 283 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.68 vs. NSPH: -80.32 )
NSPH' s 10-Year ROE (%) Range
Min: -91.21   Max: -42.93
Current: -80.32

-91.21
-42.93
ROA (%) -58.38
NSPH's ROA (%) is ranked lower than
53% of the 290 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.24 vs. NSPH: -58.38 )
NSPH' s 10-Year ROA (%) Range
Min: -212.24   Max: -38.29
Current: -58.38

-212.24
-38.29
ROC (Joel Greenblatt) (%) -312.46
NSPH's ROC (Joel Greenblatt) (%) is ranked lower than
51% of the 288 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 22.38 vs. NSPH: -312.46 )
NSPH' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -805.11   Max: -312.46
Current: -312.46

-805.11
-312.46
Revenue Growth (%) 31.70
NSPH's Revenue Growth (%) is ranked higher than
96% of the 248 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.70 vs. NSPH: 31.70 )
NSPH' s 10-Year Revenue Growth (%) Range
Min: -73.2   Max: 49.9
Current: 31.7

-73.2
49.9
EBITDA Growth (%) -27.30
NSPH's EBITDA Growth (%) is ranked higher than
52% of the 210 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 6.40 vs. NSPH: -27.30 )
NSPH' s 10-Year EBITDA Growth (%) Range
Min: 0   Max: 34.8
Current: -27.3

0
34.8
EPS Growth (%) -27.30
NSPH's EPS Growth (%) is ranked higher than
55% of the 220 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.90 vs. NSPH: -27.30 )
NSPH' s 10-Year EPS Growth (%) Range
Min: -69.8   Max: 48.1
Current: -27.3

-69.8
48.1
» NSPH's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2012

NSPH Guru Trades in Q2 2012

Jim Simons 37,400 sh (-75.22%)
» More
Q3 2012

NSPH Guru Trades in Q3 2012

Jim Simons Sold Out
» More
Q3 2013

NSPH Guru Trades in Q3 2013

John Keeley 26,000 sh (New)
Paul Tudor Jones 18,800 sh (New)
Louis Moore Bacon 75,000 sh (New)
» More
Q4 2013

NSPH Guru Trades in Q4 2013

John Keeley 26,000 sh (unchged)
Paul Tudor Jones Sold Out
Louis Moore Bacon Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with NSPH

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
John Keeley 2013-09-30 New Buy$1.83 - $3.44 $ 1.87-25%26000
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 2.90
NSPH's P/B is ranked higher than
52% of the 277 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.84 vs. NSPH: 2.90 )
NSPH' s 10-Year P/B Range
Min: 0.82   Max: 7.31
Current: 2.9

0.82
7.31
P/S 10.60
NSPH's P/S is ranked lower than
77% of the 293 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.67 vs. NSPH: 10.60 )
NSPH' s 10-Year P/S Range
Min: 8.41   Max: 188.83
Current: 10.6

8.41
188.83
EV-to-EBIT 9.00
NSPH's EV-to-EBIT is ranked higher than
91% of the 237 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 18.63 vs. NSPH: 9.00 )
NSPH' s 10-Year EV-to-EBIT Range
Min: 0   Max: 0
Current: 9

Valuation & Return

vs
industry
vs
history
Price/Net Cash 5.70
NSPH's Price/Net Cash is ranked higher than
69% of the 68 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 17.80 vs. NSPH: 5.70 )
NSPH' s 10-Year Price/Net Cash Range
Min: 1.68   Max: 6.94
Current: 5.7

1.68
6.94
Price/Net Current Asset Value 4.50
NSPH's Price/Net Current Asset Value is ranked higher than
79% of the 118 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 13.30 vs. NSPH: 4.50 )
NSPH' s 10-Year Price/Net Current Asset Value Range
Min: 1.65   Max: 5.45
Current: 4.5

1.65
5.45
Price/Tangible Book 3.50
NSPH's Price/Tangible Book is ranked higher than
63% of the 231 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.84 vs. NSPH: 3.50 )
NSPH' s 10-Year Price/Tangible Book Range
Min: 1.45   Max: 4.24
Current: 3.5

1.45
4.24
Price/Median PS Value 0.30
NSPH's Price/Median PS Value is ranked higher than
97% of the 266 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.10 vs. NSPH: 0.30 )
NSPH' s 10-Year Price/Median PS Value Range
Min: 0.42   Max: 2.32
Current: 0.3

0.42
2.32
Forward Rate of Return (Yacktman) -160.04
NSPH's Forward Rate of Return (Yacktman) is ranked lower than
53% of the 217 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.17 vs. NSPH: -160.04 )
NSPH' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 22.3   Max: 55.8
Current: -160.04

22.3
55.8

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies
Compare:WST, BAX, COV, TMO, COO » details
Traded in other countries:3NS.Germany
Nanosphere, Inc., is a Delaware Corporation. The Company develops, manufactures and markets an advanced molecular diagnostics platform, the Verigene System, that enables simple, low cost and highly sensitive genomic and protein testing on a single platform. Its proprietary nanoparticle technology provides the ability to run multiple tests simultaneously on the same sample. The Verigene System includes a bench-top molecular diagnostics workstation that is a universal platform for genomic and protein testing. While many systems currently available on the market provide a diagnostic result for one test or a few tests within a specific market niche, the Verigene System provides for multiple tests to be performed on a single platform, including both genomic and protein assays, from a single sample. The Verigene System is differentiated by its ease of use, rapid turnaround times and ability to detect many targets on a single test, referred to as 'multiplexing.' It provides lower cost for laboratories already performing molecular diagnostic testing and enables smaller laboratories and hospitals without advanced diagnostic capabilities to perform genetic testing.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide